Background. Gastric pentadecapeptide
BPC 157 therapy in rats compensated irremovable occlusion of various vessels and counteracted the consequent multiorgan dysfunction syndromes by activation of the corresponding collateral bypassing loops. Thus, we used
BPC 157 therapy against the irremovable occlusion of the end of the superior mesenteric vein. Methods. Assessments, for 30 min (gross recording, venography, ECG, pressure, microscopy, biochemistry, and oxidative stress) include the portal and caval
hypertension, aortal
hypotension, and centrally, the superior sagittal sinus
hypertension, systemic arterial and
venous thrombosis, ECG disturbances, MDA-tissue increase, and heart, lung, liver, kidney and gastrointestinal tract, in particular, and brain (cortex (cerebral, cerebellar), hypothalamus/thalamus, hippocampus) lesions. Rats received
BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min
ligation time. Results.
BPC 157 rapidly activated the superior mesenteric vein-inferior anterior pancreati-coduodenal vein-superior anterior pancreaticoduodenal vein-pyloric vein-portal vein pathway, reestablished superior mesenteric vein and portal vein connection and reestablished blood flow. Simultaneously, toward inferior caval vein, an additional pathway appears via the inferior mesenteric vein united with the middle
colic vein, throughout its left
colic branch to ascertain alternative bypassing blood flow. Consequently,
BPC 157 acts peripherally and centrally, and counteracted the intracranial (superior sagittal sinus), portal and caval
hypertension, aortal
hypotension, ECG disturbances attenuated, abolished progressing venous and arterial
thrombosis. Additionally,
BPC 157 counteracted multiorgan dysfunction syndrome, heart, lung, liver, kidney and gastrointestinal tract, and brain lesions, and oxidative stress in tissues. Conclusion.
BPC 157 therapy may be specific management also for the superior mesenteric vein
injuries.